Clinical Microbiology and Infection最新文献

筛选
英文 中文
Optimising posaconazole dosing in paediatric patients: a population pharmacokinetic modelling and simulation study. 优化泊沙康唑在儿科患者的剂量:人群药代动力学建模和模拟研究。
IF 8.7 1区 医学
Clinical Microbiology and Infection Pub Date : 2026-11-13 DOI: 10.1016/j.cmi.2026.10.035
My-Luong Vuong, Omar Elkayal, Joseph F Standing, Zoe Kane, Siân Bentley, Athanasios Tragiannidis, Andreas H Groll, Jenna Nickless, Adam Brothers, Anne Uyttebroeck, Romina Valenzuela, Jorge Morales, Geert Verbeke, Isabel Spriet, Erwin Dreesen
{"title":"Optimising posaconazole dosing in paediatric patients: a population pharmacokinetic modelling and simulation study.","authors":"My-Luong Vuong, Omar Elkayal, Joseph F Standing, Zoe Kane, Siân Bentley, Athanasios Tragiannidis, Andreas H Groll, Jenna Nickless, Adam Brothers, Anne Uyttebroeck, Romina Valenzuela, Jorge Morales, Geert Verbeke, Isabel Spriet, Erwin Dreesen","doi":"10.1016/j.cmi.2026.10.035","DOIUrl":"https://doi.org/10.1016/j.cmi.2026.10.035","url":null,"abstract":"<p><strong>Objectives: </strong>Posaconazole is approved for prophylaxis and treatment of invasive fungal infections in paediatric patients, but data for optimal formulation-specific dosing across the paediatric weight range remains scant. We pooled individual-level pharmacokinetic data to identify dosing regimens that optimise the probability of achieving predefined efficacy and safety targets.</p><p><strong>Methods: </strong>Individual concentration-time data from paediatric patients receiving posaconazole as oral suspension, delayed-release tablet, or intravenous infusion were pooled. A population pharmacokinetics model was developed using nonlinear mixed-effects modelling in NONMEM. Stochastic simulations were performed in virtual cohorts across body weights of 5-50 kg, evaluating multiple dosing regimens. Efficacy and safety were assessed as the probability of attaining a trough concentration >1 mg/L (P<sub>efficacy</sub>) and ≤4 mg/L (P<sub>safety</sub>), respectively.</p><p><strong>Results: </strong>Data from seven published studies comprising 309 paediatric patients (1050 serum concentrations) were aggregated. A one-compartment model with nonlinear (Michaelis-Menten) elimination best described the data. Suspension bioavailability decreased with increasing dose, and was further reduced by proton pump inhibitor use (-41.1%, 9.5% relative standard error, RSE) and diarrhoea (-29.5%, 21.4% RSE). Tablet bioavailability was estimated at 43.0% (10.4% RSE). For the oral suspension, neither 200 mg nor 400 mg four times daily achieved P<sub>efficacy</sub> ≥90% across weight bands. For intravenous and delayed-release tablet formulations, no regimen simultaneously achieved ≥90% P<sub>efficacy</sub> and P<sub>safety</sub> at steady state. For these two formulations, a loading dose of 12-15 mg/kg twice daily followed by 12-15 mg/kg once daily provided the most favourable balance between early efficacy and safety on day 2.</p><p><strong>Conclusions: </strong>The original oral suspension showed consistently low target attainment and is suboptimal in paediatric patients. For the intravenous and delayed-release tablet, a loading dose of 12-15 mg/kg twice daily followed by 12-15 mg/kg once daily is recommended as a starting regimen, with subsequent dose individualisation through model-informed precision dosing guided by therapeutic drug monitoring.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatitis B after switch to long-acting cabotegravir/rilpivirine: data from the SCohoLART cohort. 转换为长效卡博特韦/利匹韦林后乙型肝炎:来自SCohoLART队列的数据
IF 8.7 1区 医学
Clinical Microbiology and Infection Pub Date : 2026-11-11 DOI: 10.1016/j.cmi.2026.10.015
Angelo Roberto Raccagni, Tommaso Clemente, Riccardo Lolatto, Nicolò Capra, Serena Rolla, Hasson Hamid, Emanuela Messina, Vincenzo Spagnuolo, Elena Bruzzesi, Paola Striglia, Silvia Nozza, Antonella Castagna
{"title":"Hepatitis B after switch to long-acting cabotegravir/rilpivirine: data from the SCohoLART cohort.","authors":"Angelo Roberto Raccagni, Tommaso Clemente, Riccardo Lolatto, Nicolò Capra, Serena Rolla, Hasson Hamid, Emanuela Messina, Vincenzo Spagnuolo, Elena Bruzzesi, Paola Striglia, Silvia Nozza, Antonella Castagna","doi":"10.1016/j.cmi.2026.10.015","DOIUrl":"https://doi.org/10.1016/j.cmi.2026.10.015","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial. 在接受利妥昔单抗治疗的anca相关血管炎患者中,强化策略与标准肺炎球菌疫苗接种方案:一项多中心随机对照试验
IF 8.7 1区 医学
Clinical Microbiology and Infection Pub Date : 2026-11-10 DOI: 10.1016/j.cmi.2026.11.004
Benjamin Terrier, Laura Richert, Grégory Pugnet, Olivier Aumaître, Olivier Moranne, Noémie Huchet, Lucie Chevrier, Elisabeth Diot, Alexandre Karras, Fabrice Bonnet, Claire de Moreuil, Eric Hachulla, Thomas Le Gallou, Céline Lebas, Julien Campagne, Cédric Rafat, Maxime Samson, Jean-François Augusto, Grégoire Couvrat-Devergne, Cécile Janssen, Thierry Martin, Thomas Quemeneur, Pierre-Louis Carron, Cécile-Audrey Durel, Khalil El Karoui, Aurélie Grados, Mathieu Puyade, Marc Ruivard, Yurdagul Uzunhan, Jean-François Viallard, Xavier Puéchal, Loïc Guillevin, Corine Desaint, Hendy Abdoul, Carine Bellera, Frédéric Batteux, Odile Launay
{"title":"Reinforced strategies versus standard pneumococcal vaccination regimen in patients with ANCA-associated vasculitides receiving rituximab therapy: A Multicenter Randomized Controlled Trial.","authors":"Benjamin Terrier, Laura Richert, Grégory Pugnet, Olivier Aumaître, Olivier Moranne, Noémie Huchet, Lucie Chevrier, Elisabeth Diot, Alexandre Karras, Fabrice Bonnet, Claire de Moreuil, Eric Hachulla, Thomas Le Gallou, Céline Lebas, Julien Campagne, Cédric Rafat, Maxime Samson, Jean-François Augusto, Grégoire Couvrat-Devergne, Cécile Janssen, Thierry Martin, Thomas Quemeneur, Pierre-Louis Carron, Cécile-Audrey Durel, Khalil El Karoui, Aurélie Grados, Mathieu Puyade, Marc Ruivard, Yurdagul Uzunhan, Jean-François Viallard, Xavier Puéchal, Loïc Guillevin, Corine Desaint, Hendy Abdoul, Carine Bellera, Frédéric Batteux, Odile Launay","doi":"10.1016/j.cmi.2026.11.004","DOIUrl":"https://doi.org/10.1016/j.cmi.2026.11.004","url":null,"abstract":"<p><strong>Objectives: </strong>To assess whether reinforced pneumococcal vaccination strategies improve immunogenicity in patients with ANCA-associated vasculitis (AAV) receiving rituximab.</p><p><strong>Methods: </strong>PNEUMOVAS was a multicentre, open-label, randomized phase 2 superiority trial. Between February 2018 and May 2020, adults with newly diagnosed or relapsing granulomatosis with polyangiitis or microscopic polyangiitis scheduled for rituximab induction were randomized (1:1:1) to: standard vaccination (Arm A: one PCV13 dose at day 0 followed by PPV23 at month 5), reinforced regimen 1 (Arm B: two PCV13 doses at day 0 and two at day 7 followed by PPV23), or reinforced regimen 2 (Arm C: four PCV13 doses at day 0 followed by PPV23). The primary endpoint was the breadth of the ELISA antibody response at month 6, categorized as a response to 0-3, 4-6, 7-9, or 10-12 of 12 shared serotypes, and analyzed with an age-adjusted proportional odds model in the modified intention-to-treat population.</p><p><strong>Results: </strong>Of 120 planned patients, 96 were randomized (30, 32, and 34 in Arms A, B, and C) and 95 were analyzed (median age 62 years; 47/95 [49.5%] male; median follow-up 17.9 months). At month 6, 1/30 (3.3%), 5/32 (15.6%), and 2/33 (6.1%) participants in Arms A, B, and C responded to 7-9 serotypes, and none to 10-12. Compared with the standard regimen, Arm B significantly improved the breadth of the response (proportional OR 4.14, 97.5% CI 1.08 to 15.88; p=0.018), whereas Arm C showed a non-significant trend (pOR 3.08, 97.5% CI 0.80 to 11.92). Reinforced schedules also improved opsonophagocytic activity for several serotypes. Vaccine responses declined over time in all groups. Vaccination was overall well tolerated, with no vaccine-related serious adverse events.</p><p><strong>Conclusions: </strong>In AAV patients receiving rituximab, reinforced pneumococcal vaccination strategies improved humoral immunogenicity compared with the standard regimen (ClinicalTrials.gov Identifier: NCT03069703).</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial Intelligence for sepsis prediction: A review of real-world clinical implementation. 脓毒症预测的人工智能:现实世界临床实施的回顾。
IF 8.7 1区 医学
Clinical Microbiology and Infection Pub Date : 2026-11-10 DOI: 10.1016/j.cmi.2026.10.036
Aadith Ashok, Nenad Macesic, Anton Y Peleg
{"title":"Artificial Intelligence for sepsis prediction: A review of real-world clinical implementation.","authors":"Aadith Ashok, Nenad Macesic, Anton Y Peleg","doi":"10.1016/j.cmi.2026.10.036","DOIUrl":"https://doi.org/10.1016/j.cmi.2026.10.036","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence (AI) tools have the potential to significantly improve sepsis care by analysing numerous variables in a timely and cost-effective manner. With appropriate training and fine-tuning, AI systems can support dynamic sepsis risk prediction and may facilitate more individualised clinical assessment and management. However, their generalisability across settings and effectiveness in improving patient outcomes remain to be determined.</p><p><strong>Objectives: </strong>This narrative review draws on contemporary literature to describe the clinical implementation of AI sepsis prediction tools, their impact on patient outcomes and sepsis process measures, and the key socio-technical barriers and solutions for translating these tools into clinically reliable and scalable systems to improve sepsis care.</p><p><strong>Sources: </strong>PubMed, Web of Science, Scopus and IEEE were searched for studies on the clinical implementation of AI sepsis prediction tools. We included studies published 2019-2026 that describe or evaluate model impact on patient outcomes or process measures.</p><p><strong>Content: </strong>Implementation studies show mixed results at improving patient outcomes such as mortality and length of stay, but adoption of AI tools has shown improvements in process measures such as time to antibiotic administration. In addition to the indeterminate clinical impact, the generalisability and scalability of AI sepsis tools have been limited due to several other factors, including heterogeneity of data, alert fatigue, insufficient clinician trust, ethical concerns, algorithmic bias, and uncertainty for clinicians around how to interpret and respond to model generated predictions. We also report a minimum outcome set that future implementation studies should pre-specify and report on.</p><p><strong>Implications: </strong>Successful integration into clinical practice requires a comprehensive implementation strategy that shifts the research and design focus from improving model accuracy to one that prioritizes real-world evaluation, human-centred design and addresses workflow, training and equity concerns.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: 'Hepatitis delta in Spain: a nationwide prospective characterization of active infection and liver disease severity' by Alberola et al. 回复:Alberola等人的“西班牙的丁型肝炎:活动性感染和肝脏疾病严重程度的全国前瞻性特征”。
IF 8.7 1区 医学
Clinical Microbiology and Infection Pub Date : 2026-11-10 DOI: 10.1016/j.cmi.2026.10.023
Hui Luo, Ting Ye
{"title":"Re: 'Hepatitis delta in Spain: a nationwide prospective characterization of active infection and liver disease severity' by Alberola et al.","authors":"Hui Luo, Ting Ye","doi":"10.1016/j.cmi.2026.10.023","DOIUrl":"https://doi.org/10.1016/j.cmi.2026.10.023","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which patients with possible endocarditis should be treated as if the diagnosis were definite? An international modified Delphi study. 哪些可能患有心内膜炎的患者应该像确诊一样治疗?一项国际修正德尔菲研究。
IF 8.7 1区 医学
Clinical Microbiology and Infection Pub Date : 2026-11-09 DOI: 10.1016/j.cmi.2026.11.002
David Mokrani, Claire Amaris Hobson, Sarah Tubiana, Laurene Deconinck, Basma Basli, David T Durack, Vance G Fowler, Gilbert Habib, Bernard Iung, Jose M Miro, Bruno Hoen, Xavier Duval
{"title":"Which patients with possible endocarditis should be treated as if the diagnosis were definite? An international modified Delphi study.","authors":"David Mokrani, Claire Amaris Hobson, Sarah Tubiana, Laurene Deconinck, Basma Basli, David T Durack, Vance G Fowler, Gilbert Habib, Bernard Iung, Jose M Miro, Bruno Hoen, Xavier Duval","doi":"10.1016/j.cmi.2026.11.002","DOIUrl":"https://doi.org/10.1016/j.cmi.2026.11.002","url":null,"abstract":"<p><strong>Objectives: </strong>To identify which combinations or numbers of diagnostic criteria in possible infective endocarditis (IE) are associated with the decision to treat as IE, that is, to give a full course of endocarditis antibiotic treatment.</p><p><strong>Methods: </strong>In a two-round modified Delphi study, international IE experts rated 47 standardised vignettes covering possible IE, of which 39 formed the basis of the main analysis. On a nine-point Likert scale, they indicated whether they would treat the patient as if he or she had IE. Consensus in favour required ≥70% of ratings at 7-9 and ≤15% at 1-3; consensus against was defined symmetrically. Associations with criteria were explored by modified Poisson regression.</p><p><strong>Results: </strong>Of 137 experts, 103 completed round 1 (84 [83%] from Europe; 71 [69%] infectious disease specialists) and 98 of 102 round 2. Consensus was reached for 24 of 39 vignettes (62%): in favour of treating as IE in 22 (56%) and against in 2 (5%). Consensus in favour rose with accumulating criteria: 33% with minor criteria only, 45% with one major and one minor, and 74% with one major and two minor. Fifteen vignettes (38%) reached no consensus. In an exploratory model, consensus in favour was most strongly associated with typical (adjusted risk ratio [aRR] 12.40, 95% CI 2.11-72.93) and consistent (aRR 8.27, 1.17-58.54) major microbiological criteria and with major imaging criteria (aRR 7.37, 1.62-33.51). The criteria associated with consensus differed by valve type: imaging in native-valve and microbiological in bioprosthetic-valve vignettes.</p><p><strong>Conclusions: </strong>Expert consensus on treating possible IE as IE was reached in 62% of scenarios, almost exclusively in favour of treatment, and was most strongly associated with major criteria. These findings describe current expert views under uncertainty and do not establish the clinical benefit of treating possible IE as definite.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Finding the missing millions with tuberculosis. 寻找失踪的数百万肺结核患者。
IF 8.7 1区 医学
Clinical Microbiology and Infection Pub Date : 2026-11-09 DOI: 10.1016/j.cmi.2026.10.034
Francesca Saluzzo, Christoph Lange, Alberto L Garcia-Basteiro
{"title":"Finding the missing millions with tuberculosis.","authors":"Francesca Saluzzo, Christoph Lange, Alberto L Garcia-Basteiro","doi":"10.1016/j.cmi.2026.10.034","DOIUrl":"https://doi.org/10.1016/j.cmi.2026.10.034","url":null,"abstract":"<p><p>Tuberculosis remains the world's leading cause of death from a single microbial pathogen. Approximately 2.4 million of an estimated 10.7 million annual cases are still missed. In order to achieve a substantial decrease of the global tuberculosis burden earlier, broader, and more accessible case detection is required. A major challenge is that roughly half of people with bacteriologically confirmed tuberculosis report no symptoms, highlighting the importance of symptom-agnostic screening and active case finding. Recent guidance by the World Health Organization has expanded diagnostic options, including chest radiography, C-reactive protein, rapid molecular tests, concurrent testing of different specimen types, and new near-point-of-care nucleic acid amplification tests. Alternative, non-sputum specimens such as tongue swabs, stool, urine, exhaled breath, and blood may improve access for children, people living with HIV, and individuals with paucibacillary or early disease. However, many emerging technologies still lack sufficient real-world performance. Ultimately, diagnostic innovation alone will not reduce the burden of tuberculosis. Effective implementation must be combined with action on poverty, malnutrition, healthcare access, and other social determinants to convert scientific progress into population-level impact, particularly across high-burden and resource-constrained settings.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transplacental transfer efficiency and longitudinal dynamics of antibodies against RSV in early childhood: a paired mother-neonate cohort study in southern China. 儿童早期抗RSV抗体的经胎盘转移效率和纵向动态:中国南方母亲-新生儿配对队列研究
IF 8.7 1区 医学
Clinical Microbiology and Infection Pub Date : 2026-11-07 DOI: 10.1016/j.cmi.2026.11.003
Meng Xu, Yan Wang, Xiaofeng Tong, Lan Yi, Jiqun Lin, Junyi Zou, Sihong Zhao, Juan Yang, Helen Y Chu, Qianli Wang, Hongjie Yu
{"title":"Transplacental transfer efficiency and longitudinal dynamics of antibodies against RSV in early childhood: a paired mother-neonate cohort study in southern China.","authors":"Meng Xu, Yan Wang, Xiaofeng Tong, Lan Yi, Jiqun Lin, Junyi Zou, Sihong Zhao, Juan Yang, Helen Y Chu, Qianli Wang, Hongjie Yu","doi":"10.1016/j.cmi.2026.11.003","DOIUrl":"https://doi.org/10.1016/j.cmi.2026.11.003","url":null,"abstract":"<p><strong>Objectives: </strong>Maternal antibodies provide early-life protection against severe respiratory syncytial virus (RSV) infection but wane rapidly. With the availability of maternal vaccine and half-life extended monoclonal antibodies for infants, understanding transplacental antibody transfer and subsequent antibody dynamics is important for optimising immunisation strategies.</p><p><strong>Methods: </strong>We conducted a longitudinal cohort study of 695 mother-neonate pairs in southern China between 2013 and 2021. Serum samples were collected from mothers at delivery and from children at birth, 2, 4, 6, 12, 24, 36 months, and 5-8 years of age. All samples were tested for RSV pre-F IgG antibodies using an enzyme-linked immunosorbent assay. A subset of samples was additionally tested for neutralizing antibodies (nAbs) using a foci reduction neutralization test.</p><p><strong>Results: </strong>Maternal and cord blood RSV pre-F IgG antibody levels were positively correlated ( = 0.87; P<0.001) with a mean transplacental transfer ratio of 1.44 (95% confidence interval [CI]: 1.40-1.47). A 10-fold increase in maternal antibody levels was associated with a 6.46-fold increase in cord blood antibody levels, corresponding to a 35% decrease in transplacental transfer ratios. Preterm birth was associated with 17% lower cord blood antibody levels than full-term birth. Maternally derived antibodies declined rapidly after birth, with an estimated half-life of 34.3 days (95% CI, 33.9-34.8); antibody levels reached a nadir at approximately 10 months of age and gradually increased thereafter. RSV pre-F IgG and nAb titers from children were strongly correlated (repeated-measures correlation: = 0.846, P < 0.001), and the correlation persisted after adjustment for age ( = 0.743, P < 0.001).</p><p><strong>Conclusions: </strong>Our findings highlight the importance of addressing lower maternally derived antibody levels in preterm infants, particularly in the context of maternal immunisation. Longitudinal antibody dynamics reveal a distinct period of low antibody levels during infancy that may inform the timing of targeted RSV immunisation strategies.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ten minutes after the injection: immediate systemic reactions to long-acting cabotegravir and rilpivirine. 注射后10分钟:立即全身反应长效卡博特韦和利匹韦林。
IF 8.7 1区 医学
Clinical Microbiology and Infection Pub Date : 2026-11-06 DOI: 10.1016/j.cmi.2026.10.040
Alejandro de Gea-Grela, José R Arribas
{"title":"Ten minutes after the injection: immediate systemic reactions to long-acting cabotegravir and rilpivirine.","authors":"Alejandro de Gea-Grela, José R Arribas","doi":"10.1016/j.cmi.2026.10.040","DOIUrl":"https://doi.org/10.1016/j.cmi.2026.10.040","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of immunomodulatory therapies on mortality in adults hospitalised with COVID-19 and non-COVID-19 community-acquired pneumonia: A systematic review and meta-analysis. 免疫调节疗法对COVID-19和非COVID-19社区获得性肺炎住院成人死亡率的影响:系统回顾和荟萃分析
IF 8.7 1区 医学
Clinical Microbiology and Infection Pub Date : 2026-11-06 DOI: 10.1016/j.cmi.2026.11.001
Luke Flower, Joseph Newman, Martin Law, Eckart De Bie, Dominique-Laurent Couturier, Elisabeth Robinson, Charlotte Edwards, Brian Nguyen, Veronica Phillips, Charlotte Summers
{"title":"Effect of immunomodulatory therapies on mortality in adults hospitalised with COVID-19 and non-COVID-19 community-acquired pneumonia: A systematic review and meta-analysis.","authors":"Luke Flower, Joseph Newman, Martin Law, Eckart De Bie, Dominique-Laurent Couturier, Elisabeth Robinson, Charlotte Edwards, Brian Nguyen, Veronica Phillips, Charlotte Summers","doi":"10.1016/j.cmi.2026.11.001","DOIUrl":"https://doi.org/10.1016/j.cmi.2026.11.001","url":null,"abstract":"<p><strong>Background: </strong>Community-acquired pneumonia (CAP) is the leading infectious cause of morbidity and mortality globally. Severe disease is driven by a dysregulated host inflammatory response, leading to tissue damage. Despite numerous immunomodulatory strategies studied in CAP, their effectiveness remains unclear.</p><p><strong>Objective: </strong>To assess the effectiveness of immunomodulatory therapies on 30-day and 90-day mortality in adults hospitalised with CAP.</p><p><strong>Methods/data sources: </strong>Medline (via Ovid), Embase (via Ovid), Web of Science (Core Collection), Scopus, and Global Health (via Ebscohost) were searched from inception to 9 December 2025.</p><p><strong>Study eligibility criteria: </strong>All studies investigating the use of immunomodulatory therapies in adult patients hospitalised with CAP.</p><p><strong>Participants: </strong>Adult patients admitted to hospital with CAP.</p><p><strong>Interventions: </strong>Any immunomodulatory therapy initiated for the management of CAP.</p><p><strong>Assessment of risk of bias: </strong>RoB2 was used for RCTs and ROBINS-I for non-randomised studies of interventions.</p><p><strong>Methods of data synthesis: </strong>Treatments were grouped into pre-specified categories, then analysed in a series of pairwise random-effects meta-analyses. Pre-specified subgroup analyses were undertaken regarding severity, aetiology and individual treatments within selected categories. COVID-19 and non-COVID-19 CAP analyses were performed separately.</p><p><strong>Results: </strong>196 studies, including 89,117 patients, were included. Nine treatment categories included five or more randomised controlled trials (RCTs) reporting 30-day mortality. Among these, corticosteroids, cytokine inhibitors (predominantly IL-6), and JAK inhibitors were associated with reduced 30-day mortality in COVID-19, with odds ratios of 0.87 (95% CI 0.765-0.999), 0.84 (95% CI 0.76-0.93), and 0.66 (95% CI 0.47-0.93), respectively. The only therapies evaluated in five or more RCTs reporting 90-day mortality were cytokine inhibitors in COVID-19 CAP (OR 0.68, 95% CI 0.45-1.03). No therapies were consistently associated with reduced mortality in non-COVID-19 CAP.</p><p><strong>Conclusions: </strong>Cytokine inhibitors reduce 30-day mortality while corticosteroids and JAK inhibitors probably reduce 30-day mortality in adults hospitalised with COVID-19 CAP. Further research is needed to identify effective immunomodulatory strategies for non-COVID-19 CAP.</p><p><strong>Systematic review registration: </strong>PROSPERO ID - CRD42024565301.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149357216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书